Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a leading clinical-stage biopharmaceutical company specializing in the development of innovative therapies for immuno-inflammatory diseases. Founded by dermatologists, Aclaris leverages its extensive expertise in dermatologic treatments to address significant unmet needs in both medical and aesthetic dermatology.
Aclaris operates primarily through two segments: therapeutics and contract research. The therapeutics segment focuses on identifying and developing novel therapies to treat immuno-inflammatory diseases. Key drug candidates in this segment include Zunsemetinib, an oral MK2 inhibitor, ATI-2138, an ITJ inhibitor, and ATI-1777, a topical JAK 1/3 inhibitor. The contract research segment generates revenue by offering laboratory services, which constitute a significant portion of the company’s revenue.
Recent milestones for Aclaris include the progression of ATI-2138 into Phase 2a proof-of-concept trials for T cell-mediated autoimmune diseases and the completion of enrollment for the ATI-1777 Phase 2b trial in atopic dermatitis. Preliminary data from these trials have shown promising results, paving the way for further clinical development. Aclaris has also announced partnerships with institutions like Washington University to explore additional therapeutic applications for its drug candidates.
Financially, Aclaris maintains a robust liquidity position. As of the end of 2023, the company holds approximately $181.9 million in cash, cash equivalents, and marketable securities, ensuring the capability to fund operations through 2025. Revenue generation is primarily driven by contract research services and strategic licensing agreements, such as the recent deal with Sun Pharmaceutical Industries, Inc., which grants exclusive rights under certain patents for the use of deuruxolitinib in treating alopecia areata and androgenetic alopecia.
Aclaris Therapeutics (Nasdaq:ACRS) has priced its underwritten public offering of 5,483,714 shares at $17.50 each, targeting gross proceeds of approximately $96 million. The offering includes a 30-day option for underwriters to purchase an additional 822,557 shares. Expected to close on or about January 22, 2021, this capital raise, facilitated by Cantor Fitzgerald & Co. and William Blair & Company, aims to support Aclaris' ongoing clinical-stage development in immuno-inflammatory diseases.
Aclaris Therapeutics (Nasdaq: ACRS) announced its intention to conduct an underwritten public offering of its common stock, subject to market conditions. The offering will include a 30-day option for underwriters to purchase an additional 15% of the shares. Cantor Fitzgerald & Co. and William Blair & Company are joint book-running managers for the offering. A shelf registration statement for these shares was filed with and declared effective by the SEC. The offering will be made via a prospectus supplement and will not constitute an offer without proper registration.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced promising topline results from a 12-week, Phase 2a trial of ATI-450, an investigational oral MK2 inhibitor, for rheumatoid arthritis. The study showed durable clinical activity, with a significant 2.0 reduction in DAS28-CRP scores and 40% of treatment subjects achieving low disease activity by week 12. ATI-450 was generally well tolerated, with no serious adverse events reported. The company plans to advance ATI-450 to Phase 2b trials and publish full data analysis in a scientific journal.
Aclaris Therapeutics (ACRS) announced the establishment of a new Scientific Advisory Board comprising leading experts in immuno-inflammatory diseases. The board includes Drs. Stanley Cohen, Marco Colonna, James Krueger, and Michael Weinblatt, who bring extensive experience in rheumatology and immunology. Additionally, Aclaris expects preliminary topline data from the ATI-450-RA-201 Phase 2a trial for rheumatoid arthritis in January 2021. This development aims to enhance Aclaris’ R&D efforts in addressing unmet medical needs in immuno-inflammatory conditions.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 7:30 a.m. ET. Management will also be available for one-on-one virtual meetings on December 1 and 2. Investors can access a live audio webcast of the event through the company's website, with an archived version available for 30 days. Aclaris is focused on developing novel drug candidates for immuno-inflammatory diseases, supported by a robust R&D platform.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its Q3 2020 financial results and progress updates on clinical trials. The company initiated a Phase 2a trial of ATI-1777 for atopic dermatitis and dosed the first subject. Additionally, a Phase 2a trial for ATI-450 in cryopyrin-associated periodic syndrome commenced. Financial highlights included a net loss of $10.7 million for Q3 2020 compared to $55.3 million in Q3 2019, and total revenue increased to $1.4 million, up from $1.0 million. Aclaris reported cash reserves of $55.2 million as of September 30, 2020, sufficient for operations through Q1 2022.
Aclaris Therapeutics (NASDAQ: ACRS) announced the dosing of the first patient in its Phase 2a clinical trial for ATI-1777, a topical JAK 1/3 inhibitor targeting moderate to severe atopic dermatitis (AD). The trial, enrolling approximately 42 subjects across multiple sites in the U.S., aims to assess the drug's efficacy, safety, and pharmacokinetics over 28 days. The primary endpoint is the change in the Eczema Area and Severity Index (EASI) score at week 4. The trial marks a significant step in Aclaris’ development of novel treatments for immuno-inflammatory diseases.
On September 1, 2020, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, 2020, at 12:30 p.m. ET, featuring a presentation by President and CEO Dr. Neal Walker. The second event is the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 10:40 a.m. ET, where Dr. Walker will take part in a fireside chat. Live webcasts will be available on the company’s website for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) received FDA approval for an investigational new drug application to study ATI-450 in hospitalized COVID-19 patients. This Phase 2a trial, led by the University of Kansas Medical Center, aims to evaluate the efficacy of ATI-450 in mitigating cytokine release syndrome (CRS) in 36 patients. The study's primary endpoint is the proportion of patients free from respiratory failure by day 14. ATI-450 has shown potential in reducing multiple inflammatory cytokines, indicating its promise in addressing severe COVID-19 symptoms.
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics (NASDAQ: ACRS) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET. The presentation will provide a company overview, which can be accessed via a live audio webcast on Aclaris’ website, with an archived version available for 30 days. Aclaris is dedicated to treating immuno-inflammatory diseases, featuring a diverse portfolio that includes a late-stage drug candidate supported by a strong R&D initiative.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
What is Aclaris Therapeutics, Inc. focused on?
What are the key drug candidates Aclaris is developing?
What recent clinical trial milestones has Aclaris achieved?
How does Aclaris generate revenue?
What was the recent licensing agreement with Sun Pharmaceutical Industries about?
What is Aclaris' financial position as of the end of 2023?
What partnerships does Aclaris have for clinical development?
What is the significance of ATI-2138's recent trial results?
What is the focus of Aclaris' therapeutics segment?
What makes Aclaris unique in the biopharmaceutical industry?
